Agilent Combines Its Life Sciences and Diagnostics Businesses

News   Sep 19, 2013

 
Agilent Combines Its Life Sciences and Diagnostics Businesses
 
 
 

RELATED ARTICLES

Neuropeptide Y Y1 Receptor Structure Solved, Offers New Opportunities for Anti-obesity Drug Discovery

News

Scientists solve the crystal structure of Neuropeptide Y Y1 Receptor, offering new opportunities for anti-obesity drug discovery.

READ MORE

Crystal Structure of Neuropeptide 1 Receptor Solved, Providing Therapeutic Angle For Obesity Treatment

News

An international team has uncovered the potential to beat obesity at the cellular level, characterizing for the first time a complex, little-understood receptor type that, when activated, shuts off hunger.

READ MORE

The End of the Breathalyzer?

News

Engineers have developed a miniature, ultra-low power injectable biosensor that could be used for continuous, long-term alcohol monitoring. The chip is small enough to be implanted in the body just beneath the surface of the skin and is powered wirelessly by a wearable device, such as a smartwatch or patch.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Analysis & Separations Genomics Research Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE